Back to today’s briefing

Story perspectives

Study Reveals Testing Gaps in Ovarian, Breast Cancer Care

3/25/2025

29 5

Summary

Story summary

A recent study in JCO Oncology Advances reveals a troubling trend: many patients with epithelial ovarian cancer and metastatic breast cancer are not receiving crucial testing for homologous repair deficiency and BRCA1/2 mutations. This gap is especially pronounced among non-White patients and those with low-grade tumors. Increasing testing access could pave the way for more effective PARP inhibitor treatments, offering hope for better outcomes.

1 of 1

Story summary

A recent study in JCO Oncology Advances reveals a troubling trend: many patients with epithelial ovarian cancer and metastatic breast cancer are not receiving crucial testing for homologous repair deficiency and BRCA1/2 mutations. This gap is especially pronounced among non-White patients and those with low-grade tumors. Increasing testing access could pave the way for more effective PARP inhibitor treatments, offering hope for better outcomes.